Woodline Partners LP Trims Stock Holdings in Align Technology, Inc. $ALGN

Key Points

• Woodline Partners LP reduced its stake in Align Technology, Inc. by 25.5%, selling 20,675 shares in the first quarter, which left them with 60,284 shares valued at approximately $9.58 million.
• Several institutional investors, including Vanguard Group Inc. and Ninety One UK Ltd., have increased their holdings, with Federated Hermes raising its stake by an impressive 510.3%.
• Align Technology's stock has a current market capitalization of $9.85 billion and reported a net margin of 11.04% along with a Q3 2025 guidance for earnings per share.

Woodline Partners LP lessened its stake in shares of Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 25.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,284 shares of the medical equipment provider's stock after selling 20,675 shares during the quarter. Woodline Partners LP owned about 0.08% of Align Technology worth $9,577,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Align Technology by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider's stock worth $1,341,031,000 after purchasing an additional 185,187 shares during the last quarter. Ninety One UK Ltd raised its stake in shares of Align Technology by 58.7% during the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider's stock worth $307,800,000 after purchasing an additional 716,954 shares during the last quarter. Invesco Ltd. raised its stake in shares of Align Technology by 12.7% during the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider's stock worth $193,764,000 after purchasing an additional 137,553 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Align Technology by 0.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider's stock worth $117,022,000 after purchasing an additional 4,789 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Align Technology by 510.3% during the first quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider's stock worth $112,396,000 after purchasing an additional 591,588 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company's stock.

Align Technology Stock Performance

Align Technology stock opened at $135.91 on Friday. The firm has a market capitalization of $9.85 billion, a price-to-earnings ratio of 22.92, a price-to-earnings-growth ratio of 1.50 and a beta of 1.65. Align Technology, Inc. has a fifty-two week low of $127.70 and a fifty-two week high of $262.87. The stock's fifty day moving average is $161.93 and its two-hundred day moving average is $170.56.

Align Technology (NASDAQ:ALGN - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.08). The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the company posted $2.41 EPS. Align Technology has set its Q3 2025 guidance at EPS. As a group, sell-side analysts forecast that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has authorized a stock buyback plan on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms have recently commented on ALGN. Mizuho set a $210.00 price target on Align Technology in a research note on Thursday, July 31st. Stifel Nicolaus dropped their price objective on Align Technology from $275.00 to $200.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. Piper Sandler dropped their price objective on Align Technology from $250.00 to $190.00 and set an "overweight" rating on the stock in a report on Thursday, July 31st. Zacks Research lowered Align Technology from a "hold" rating to a "strong sell" rating in a report on Monday, September 1st. Finally, Evercore ISI upped their price objective on Align Technology from $200.00 to $220.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Align Technology currently has an average rating of "Moderate Buy" and an average target price of $215.00.

Insiders Place Their Bets

In other news, CEO Joseph M. Hogan bought 7,576 shares of the stock in a transaction on Friday, August 1st. The shares were bought at an average price of $131.49 per share, with a total value of $996,168.24. Following the completion of the acquisition, the chief executive officer owned 184,945 shares of the company's stock, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.66% of the company's stock.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.